A new corporate VC fund formed by a biopharmaceutical company is looking to invest in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is currently open to opportunities worldwide.
The firm is currently looking to invest in three indication areas: oncology, immunology, and hematology. The fund is technology-agnostic, and is therefore interested in therapeutic, medical device, diagnostic and healthcare IT opportunities in these three areas. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).
The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment